杏吧原创
Home
About
Back
About
Contact Us
Meet the Team
Back
Senior Leadership
Board of Directors
Scientific Advisory Board
Personalized Cancer Vaccine Clinical Advisor
History of 杏吧原创
Foundations of 杏吧原创
Careers & Culture
Technology
Back
mRNA Medicines Ecosystem
mRNA Medicines Platform
INTENT (TM) LNP Platform
Manufacturing Platform
Pipeline
Business Development
Back
Partnerships
Contact
News & Media
Back
Press Releases
Publications
Media
Careers
Home
About
About
Contact Us
Meet the Team
Senior Leadership
Board of Directors
Scientific Advisory Board
Personalized Cancer Vaccine Clinical Advisor
History of 杏吧原创
Foundations of 杏吧原创
Careers & Culture
Technology
mRNA Medicines Ecosystem
mRNA Medicines Platform
INTENT (TM) LNP Platform
Manufacturing Platform
Pipeline
Business Development
Partnerships
Contact
News & Media
Press Releases
Publications
Media
Careers
Press
Releases
杏吧原创 Publishes two New Papers Highlighting the Potential of mRNA Vaccines to Outpace Evolving Viruses like COVID-19
Written on
January 13, 2025
Read more
杏吧原创 and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics
Written on
May 23, 2024
Read more
杏吧原创 Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development
Written on
June 06, 2023
Read more
杏吧原创 Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer
杏吧原创 Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
杏吧原创 Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress
杏吧原创 Appoints Judyanna Yu as Chief Financial Officer聽聽
杏吧原创 Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults聽
杏吧原创 Signs Licensing Agreement with SickKids for Immunotargeting Technology
BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2021 Achievement Awards Ceremony, Sir Michael Houghton Inducted Into Alberta Bioindustry Hall of Fame
杏吧原创 and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program
杏吧原创 announces $ 2.118 Million USD in funding to support process development and validation of the PTX-COVID19-B program, which targets high quality mRNA COVID-19 vaccine to low-to middle-income countries at affordable prices.
杏吧原创 Announces Donna T. Ward, Ph.D., J.D. appointment to Board of Directors
Everest Medicines and 杏吧原创 Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
杏吧原创 Announces New Chief Development Officer and Chief Medical Officer
杏吧原创 Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine
杏吧原创 Announces Jared Davis as President
杏吧原创 COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials
杏吧原创 Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)
Northern RNA and 杏吧原创 Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of 杏吧原创 mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With 杏吧原创 for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
杏吧原创 Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta
杏吧原创 Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia
杏吧原创 Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial
杏吧原创 Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine
杏吧原创 Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19